November 18, 2026
Health news, explained with evidence
LIVE

Erectile Dysfunction Medication Mirodenafil Yields Mixed Results in Phase III Alzheimer's Trial

❤️ Conditions & Care 2 min read 👁 4

An oral phosphodiesterase-5 inhibitor originally approved for erectile dysfunction missed its main overall goal in a major Alzheimer's study, though a specific subgroup showed a slower rate of cognitive decline.

Erectile Dysfunction Medication Mirodenafil Yields Mixed Results in Phase III Alzheimer's Trial❤️Conditions & Care

Photo: medpagetoday.com

Key points

  • The POLARIS-AD trial tested mirodenafil, an oral phosphodiesterase-5 inhibitor, in 1,535 early Alzheimer's patients over 52 weeks.
  • The study missed its primary endpoint in the overall population but showed a significant 31% slowing of decline in a monotherapy subgroup.
  • Experts caution that these findings are early, and individuals must not use erectile dysfunction drugs to self-treat Alzheimer's.

A phase III clinical trial evaluating the oral medication mirodenafil, known as AR1001, has reported mixed outcomes for patients in the early stages of Alzheimer's disease. Sharon Sha, MD, MS, of Stanford University presented the findings from the POLARIS-AD study at the Clinical Trials on Alzheimer's Disease conference in Boston.

Looking at the entire participant group, the drug did not achieve a statistically significant difference compared to a placebo on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) scale over a 52-week period. However, in a prespecified subgroup of patients who were not taking standard Alzheimer's medications like acetylcholinesterase inhibitors or memantine at baseline, the treatment demonstrated a statistically significant slowing of cognitive and functional decline by 31%.

What to know: The trial encompassed 1,535 participants with mild cognitive impairment or mild dementia, with an average age of 73. While secondary measures leaned favorably toward the therapy and biomarker tests confirmed target engagement by increasing cyclic GMP levels in cerebrospinal fluid, experts caution that the overall primary endpoint was missed and side effects included diarrhea, falls, and dizziness. Patients should always consult a qualified physician regarding any medical treatment decisions, and experts emphasize that individuals should not attempt to use medications like Viagra for Alzheimer's management.

AR1001 takes a novel approach, relaxing blood vessels to increase blood flow to the brain. — Richard Oakley, PhD

Trial safety data revealed that serious adverse events occurred at similar rates between the treatment and placebo groups. Discontinuations due to adverse effects were reported in 5.2% of the medication group versus 1.7% of the placebo group, and a small number of fatalities occurred across both arms of the study.

Source medpagetoday.com — medpagetoday.com/meetingcoverage/ctad/123938 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.